CJC-1295 Peptide Buyer's Guide: What Researchers Need (2026)

If you're a qualified researcher sourcing CJC-1295 peptide for endocrine, metabolic, or peptide-signalling studies, the purchasing decision is more nuanced than price alone. Purity documentation, DAC vs. no-DAC formulation, and vendor certification standards all affect whether your data holds up to scrutiny. PeptideValidation.com supplies research-grade CJC-1295 as a 5 mg lyophilized powder, produced specifically for controlled laboratory investigations of growth-hormone-releasing pathways. This guide covers what to look for before you order, not for human or veterinary use.

What Is CJC-1295 Peptide?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) containing 30 amino acids. It binds GHRH receptors and stimulates pulsatile growth hormone secretion in laboratory models. The DAC (Drug Affinity Complex) variant extends plasma half-life to approximately 6 to 8 days by covalently binding albumin, while the no-DAC form (also called Modified GRF 1-29) has a half-life closer to 30 minutes.

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) containing 30 amino acids. It binds GHRH receptors and stimulates pulsatile growth hormone secretion in laboratory models. The DAC (Drug Affinity Complex) variant extends plasma half-life to approximately 6 to 8 days by covalently binding albumin, while the no-DAC form, also called Modified GRF 1-29, has a half-life closer to 30 minutes.

Understanding that distinction matters before you design a dosing protocol or interpret results. The two forms behave differently in vitro and in animal models, and conflating them introduces variables that can undermine reproducibility.

A common question among new researchers: is CJC-1295 a steroid? No. It is a peptide, not a steroidal compound. It shares no structural or mechanistic relationship with anabolic steroids. Its mechanism is upstream, it prompts the pituitary to release endogenous growth hormone rather than supplying an exogenous hormone directly.

Because CJC-1295 research sits at the intersection of endocrinology and peptide signalling, it attracts labs studying growth hormone secretion kinetics, metabolic signalling pathways, and receptor binding dynamics. If that describes your work, getting the formulation choice right from the start saves time and reagent budget.

DAC vs. No-DAC: Which Form Should Your Lab Use?

CJC-1295 with DAC and CJC-1295 without DAC differ primarily in half-life and dosing frequency. DAC extends albumin binding to produce sustained GH elevation over days. No-DAC mimics the pulsatile GHRH pattern more closely, making it better suited for studies requiring short-duration or pulsatile GH stimulation protocols.

CJC-1295 with DAC is the go-to for protocols requiring sustained, steady-state GH elevation. Because its plasma half-life stretches to roughly 6 to 8 days in mammalian models, dosing frequency drops significantly compared to the no-DAC version. That makes it practical for longer-duration animal studies where frequent injection would itself become a confounding variable.

CJC-1295 without DAC, Modified GRF 1-29, is a better fit when your protocol calls for mimicking the physiological pulsatile pattern of GHRH release. Its 30-minute half-life means GH spikes sharply and falls quickly, which is what you need if you're measuring pulsatile secretion, testing receptor desensitisation, or pairing it with a secretagogue like ipamorelin for combination studies.

From a CJC-1295 with DAC dosage standpoint, published preclinical research has commonly explored single-dose and repeat-dose schedules in the range of micrograms per kilogram in rodent models. Always match your dosage to your species, endpoint, and protocol rather than copying a figure from a different study's supplemental materials.

PeptideValidation.com provides the CJC-1295 DAC peptide formulation as a lyophilized powder, which preserves stability during shipping and allows reconstitution at the concentration your specific protocol requires. Check your vendor's technical documentation to confirm which variant, DAC or no-DAC, is in the vial before you reconstitute.

COA Standards: The Baseline Every Batch Must Meet

A compliant COA for research-grade CJC-1295 must include: (1) peptide identity confirmation, (2) HPLC purity percentage, (3) mass spectrometry molecular weight verification, (4) batch and lot number, (5) manufacturing date, (6) recommended storage conditions, and (7) third-party laboratory name and accreditation details.

A Certificate of Analysis is not a marketing document, it is an analytical record. If a supplier cannot produce a batch-specific COA, that is a disqualifying signal regardless of price.

At minimum, a compliant COA for CJC-1295 should show HPLC purity at or above 98%, mass spectrometry confirmation of the correct molecular weight (approximately 3367 Da for the no-DAC form; higher for the DAC conjugate), and the issuing laboratory's name and accreditation status. Batch-specific means the document references the exact lot number on your vial, not a generic certificate pulled from a previous production run.

Third-party testing adds a layer of independence that in-house testing cannot. An external ISO 17025-accredited lab has no financial incentive to pass a borderline batch, which is exactly the objectivity reproducible research demands.

Peptide content verification, sometimes called amino acid analysis, is worth requesting separately if your study is sensitive to exact molar dosing. HPLC purity tells you what fraction of the material is your target peptide; amino acid analysis tells you how much of the weighed powder is actually peptide versus counterion salts or residual moisture. For pharmacokinetic or receptor-binding studies, that distinction can shift your effective dose by 10 to 15%.

For guidance on reading and verifying these documents, PeptideValidation.com's complete CJC-1295 research guide walks through each section of a model COA in detail.

CJC-1295 Peptide Benefits Under Laboratory Investigation

In preclinical research, CJC-1295 peptide benefits studied include stimulation of pulsatile GH release, increased IGF-1 concentrations in animal models, extended half-life effects with the DAC variant, and utility as a tool compound for mapping GHRH receptor binding dynamics.

The phrase 'CJC-1295 peptide benefits' shows up constantly in research forums, but it is worth being precise about context. The outcomes studied in laboratory settings are not clinical claims. They are tool-compound observations recorded under controlled conditions, typically in rodent or in vitro models.

With that framing in place, here is what published preclinical literature has explored. CJC-1295 reliably stimulates pulsatile GH release in mammalian models by binding GHRH receptors at the pituitary. Secondary to that GH spike, researchers have observed corresponding rises in IGF-1 concentrations in serum samples, which makes CJC-1295 a useful probe for studying the GH/IGF-1 axis without introducing exogenous GH itself.

The DAC variant has been used specifically to study what sustained, non-pulsatile GHRH receptor stimulation does over time, including receptor downregulation kinetics and downstream metabolic signalling. That is distinct research from pulsatile-pattern studies, and the two should not be compared as if they were equivalent protocols.

CJC-1295 is also used as a reference compound in combination studies, paired with ghrelin mimetics, for example, to produce synergistic GH release for in vivo secretion mapping. Its well-characterised receptor binding profile makes it a reliable baseline when a second variable compound is being evaluated.

None of the above constitutes evidence for human therapeutic use. All referenced work is preclinical, and CJC-1295 supplied by PeptideValidation.com is intended exclusively for laboratory research by qualified personnel.

CJC-1295 Side Effects: What Preclinical Data Shows

Preclinical studies reporting CJC-1295 side effects in animal models have noted transient injection-site reactions, water retention at higher doses, and suppression of endogenous GHRH pulsatility with prolonged DAC administration. These observations are from controlled laboratory settings and do not constitute clinical safety data for human use.

Researchers frequently search for CJC-1295 side effects before incorporating the compound into a protocol, and that is sensible due diligence. Animal studies have noted a few recurring observations worth knowing.

The most commonly reported effects at higher dose ranges in rodent studies include transient injection-site reactions and increased water retention, likely mediated by downstream IGF-1 activity. With extended DAC administration, some studies have noted blunting of the endogenous pulsatile GHRH pattern, which is relevant if your study is trying to measure baseline pulsatility rather than pharmacologically driven GH release.

At research-relevant doses, these effects have generally been reversible after the compound clears. But 'reversible in a rodent study' is not a safety claim for any other context. CJC-1295 from PeptideValidation.com is produced for controlled laboratory research only. It is not approved, evaluated, or intended for administration to humans or animals outside a regulated research protocol.

If your institutional review board or IACUC requires a compound-specific safety briefing as part of protocol approval, the COA and any available published preclinical safety data are the appropriate documents to reference. Always follow your institution's chemical handling and storage protocols for research peptides.

What to Look for When Evaluating a CJC-1295 Peptide Supplier

Key criteria for evaluating a CJC-1295 peptide supplier include: batch-specific COA availability, HPLC purity above 98%, third-party mass spectrometry confirmation, transparent sourcing documentation, lyophilized formulation for stability, responsive technical support, and clear research-use-only compliance language.

Sourcing a CJC-1295 peptide is not the same as buying a commodity reagent off a shelf. The verification burden sits with the researcher, and that means vetting the supplier before the vial arrives.

Start with COA availability. A legitimate research-grade supplier will provide a batch-specific COA on request, or better, display it directly against the product listing, before purchase. If the COA is only available 'upon request after you order', that is worth pausing on.

Next, check the purity figure and the method used to determine it. HPLC is the standard. Some vendors inflate apparent purity by using less discriminating methods. HPLC above 98% from a named, accredited external lab is the floor for compounds used in publishable research.

Lyophilized powder is the correct physical form for CJC-1295 shipped and stored at scale. Pre-dissolved peptides degrade faster, and temperature excursions during shipping become much more damaging. The 5 mg lyophilized format that PeptideValidation.com supplies allows researchers to reconstitute at the exact concentration their protocol specifies, reducing waste and dosing error.

Finally, look at the language on the product page. A compliant vendor is explicit that the material is for research use only and not for human or veterinary administration. Vague or absent compliance language is a signal that quality controls elsewhere may be equally loose.

For a detailed breakdown of vendor evaluation criteria, including what the Peptide Validation certification process actually checks, see the full CJC-1295 research resource linked below.

Storage, Reconstitution, and Handling Basics for Lab Use

Lyophilized CJC-1295 should be stored at -20 degrees Celsius, protected from light and moisture. Reconstitute with sterile bacteriostatic water or acetic acid solution depending on downstream use. Once reconstituted, store at 4 degrees Celsius and use within 28 days to maintain peptide integrity.

Proper handling starts before the vial is opened. Lyophilized CJC-1295 should be stored at -20 degrees Celsius in a dry, dark environment. Moisture and UV exposure both accelerate degradation, even in the powder state. Do not repeatedly freeze and thaw a single vial, aliquot before freezing if your protocol spans multiple sessions.

Reconstitution solvent choice depends on your downstream assay. Bacteriostatic water (0.9% benzyl alcohol) is the most common choice for peptides destined for in vivo injection in animal models because it inhibits microbial growth over a multi-week period. Some researchers use dilute acetic acid (0.1 to 1%) for peptides that are poorly soluble in neutral aqueous solutions, though CJC-1295 is generally water-soluble at research concentrations.

Add solvent slowly down the side of the vial, never inject directly onto the lyophilized cake, as the pressure can cause foaming and peptide aggregation. Swirl gently rather than vortexing. Once reconstituted, label the vial with the date, concentration, and lot number, and store at 4 degrees Celsius.

Usability window varies with peptide and storage conditions, but 28 days at 4 degrees Celsius is a conservative, widely cited figure for reconstituted GHRH analogues. Run a fresh mass spec or HPLC check on reconstituted material if your experiment extends beyond that window or if the solution shows visible particulates or colour change.

These are general laboratory handling principles. Always defer to your institution's standard operating procedures and the specific guidance in your supplier's technical documentation.

Frequently asked questions

What is CJC-1295 peptide used for in research?

In controlled laboratory settings, CJC-1295 is used as a tool compound for studying growth-hormone-releasing hormone (GHRH) receptor binding, pulsatile GH secretion, and GH/IGF-1 axis signalling. It is used exclusively for research purposes and is not approved for human or veterinary use.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC uses a Drug Affinity Complex that covalently binds albumin, extending plasma half-life to approximately 6 to 8 days. The no-DAC form (Modified GRF 1-29) has a half-life of around 30 minutes, producing short, pulsatile GH stimulation. The choice depends on whether your protocol requires sustained or pulsatile GH elevation.

What purity level should research-grade CJC-1295 meet?

Research-grade CJC-1295 should have HPLC-confirmed purity at or above 98%, supported by a batch-specific COA from a named, accredited third-party laboratory. Mass spectrometry confirmation of the correct molecular weight is also a standard requirement for credible research compounds.

Is CJC-1295 a steroid?

No. CJC-1295 is a synthetic peptide analogue of GHRH, not a steroid. It contains 30 amino acids and works by stimulating the pituitary to release endogenous growth hormone. It shares no structural or pharmacological relationship with anabolic steroids.

What side effects has CJC-1295 shown in preclinical studies?

Animal studies have recorded transient injection-site reactions, water retention at higher doses, and blunting of endogenous pulsatile GHRH patterns with prolonged DAC administration. These are preclinical observations only and do not constitute clinical safety data for any use outside a controlled research setting.

How should lyophilized CJC-1295 be stored and reconstituted?

Store lyophilized CJC-1295 at -20 degrees Celsius, protected from light and moisture. Reconstitute slowly with bacteriostatic water or dilute acetic acid depending on your assay. Once reconstituted, store at 4 degrees Celsius and use within 28 days. Always follow your institution's standard operating procedures.

Related in this series

• CJC-1295 Peptide Buyer's Guide: What Researchers Need (2026)